Buscar
Mostrando ítems 1-10 de 101
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma
(SPRINGER, 2010)
Gemcitabine is a chemotherapy agent that may cause unpredictable side effects. In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. A 72-year-old ...
Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine
(Soc Experimental Biology Medicine, 2010-07-01)
Currently, the combination of cisplatin and gemcitabine is considered a standard chemotherapeutic protocol for bladder cancer. However, the mechanism by which these drugs act on tumor cells is not completely understood. ...
Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine
(Soc Experimental Biology Medicine, 2010-07-01)
Currently, the combination of cisplatin and gemcitabine is considered a standard chemotherapeutic protocol for bladder cancer. However, the mechanism by which these drugs act on tumor cells is not completely understood. ...
Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine
(SOC EXPERIMENTAL BIOLOGY MEDICINE, 2010)
Currently, the combination of cisplatin and gemcitabine is considered a standard chemotherapeutic protocol for bladder cancer. However, the mechanism by which these drugs act on tumor cells is not completely understood. ...
MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells
(Springer, 2014-07-01)
The combination of gemcitabine and cisplatin has been shown previously to elicit a synergistic therapeutic effect on bladder cancer cell lines and result in reduced cell survival. However, the precise mechanism by which ...
Antineoplastic mechanism of gemcitabine on tumor cells with different TP53/p53 subtypes
(2014-07-01)
The aim of this chapter is to provide updated information on the mechanisms by which gemcitabine acts on tumor cells with different TP53 gene backgrounds. Currently, the genetic backgrounds of tumors and patients have been ...
Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine
(Soc Experimental Biology Medicine, 2014)
Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes
(Springer, 2012-12-01)
Because of its lower toxicity and good tolerability and response, gemcitabine has been described as one of the most highly promising drugs for urinary bladder cancer therapy. Its phosphorylated active-dFdCTP metabolite can ...
Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes
(Springer, 2012-12-01)
Because of its lower toxicity and good tolerability and response, gemcitabine has been described as one of the most highly promising drugs for urinary bladder cancer therapy. Its phosphorylated active-dFdCTP metabolite can ...
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma
(Springer, 2010-02-01)
Gemcitabine is a chemotherapy agent that may cause unpredictable side effects. in this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. A 72-year-old ...